Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
PBYI's Cash to Debt is ranked higher than
76% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. PBYI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PBYI' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: 10000.00 Max: No Debt
Current: No Debt

Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6548
N/A
No Debt
Interest Coverage No Debt
PBYI's Interest Coverage is ranked higher than
52% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PBYI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PBYI' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: 26.24
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -103.94
PBYI's ROE (%) is ranked lower than
82% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. PBYI: -103.94 )
Ranked among companies with meaningful ROE (%) only.
PBYI' s ROE (%) Range Over the Past 10 Years
Min: -141.23  Med: -66.24 Max: -37.64
Current: -103.94
-141.23
-37.64
ROA (%) -90.70
PBYI's ROA (%) is ranked lower than
85% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. PBYI: -90.70 )
Ranked among companies with meaningful ROA (%) only.
PBYI' s ROA (%) Range Over the Past 10 Years
Min: -1700  Med: -89.05 Max: -36.94
Current: -90.7
-1700
-36.94
ROC (Joel Greenblatt) (%) -9742.75
PBYI's ROC (Joel Greenblatt) (%) is ranked lower than
87% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. PBYI: -9742.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PBYI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -7408.23  Med: -5178.74 Max: -2978.59
Current: -9742.75
-7408.23
-2978.59
EBITDA Growth (3Y)(%) 53.30
PBYI's EBITDA Growth (3Y)(%) is ranked higher than
93% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. PBYI: 53.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PBYI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 26.65 Max: 598.6
Current: 53.3
0
598.6
EPS Growth (3Y)(%) 53.00
PBYI's EPS Growth (3Y)(%) is ranked higher than
92% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. PBYI: 53.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PBYI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 53  Med: 635.50 Max: 883.9
Current: 53
53
883.9
» PBYI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

PBYI Guru Trades in Q4 2014

Jim Simons Sold Out
RS Investment Management Sold Out
» More
Q1 2015

PBYI Guru Trades in Q1 2015

Steven Cohen 9,100 sh (New)
» More
Q2 2015

PBYI Guru Trades in Q2 2015

Jeremy Grantham 1,426,738 sh (New)
Steven Cohen 68,600 sh (+653.85%)
» More
Q3 2015

PBYI Guru Trades in Q3 2015

Jim Simons 162,600 sh (New)
Steven Cohen 554,019 sh (+707.61%)
Jeremy Grantham 1,676,678 sh (+17.52%)
» More
» Details

Insider Trades

Latest Guru Trades with PBYI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.87
PBYI's P/B is ranked lower than
68% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: 3.11 vs. PBYI: 4.87 )
Ranked among companies with meaningful P/B only.
PBYI' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 62.4
Current: 4.87
0
62.4
Current Ratio 10.05
PBYI's Current Ratio is ranked higher than
75% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. PBYI: 10.05 )
Ranked among companies with meaningful Current Ratio only.
PBYI' s Current Ratio Range Over the Past 10 Years
Min: 0.67  Med: 5.75 Max: 91.42
Current: 10.05
0.67
91.42
Quick Ratio 10.05
PBYI's Quick Ratio is ranked higher than
75% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. PBYI: 10.05 )
Ranked among companies with meaningful Quick Ratio only.
PBYI' s Quick Ratio Range Over the Past 10 Years
Min: 0.67  Med: 5.75 Max: 91.42
Current: 10.05
0.67
91.42

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.40
PBYI's Price/Net Cash is ranked lower than
53% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 5.23 vs. PBYI: 5.40 )
Ranked among companies with meaningful Price/Net Cash only.
PBYI' s Price/Net Cash Range Over the Past 10 Years
Min: 4.69  Med: 16.36 Max: 60.47
Current: 5.4
4.69
60.47
Price/Net Current Asset Value 5.24
PBYI's Price/Net Current Asset Value is ranked lower than
54% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 4.85 vs. PBYI: 5.24 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PBYI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 4.26  Med: 15.48 Max: 55.83
Current: 5.24
4.26
55.83
Price/Tangible Book 4.88
PBYI's Price/Tangible Book is ranked lower than
61% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. PBYI: 4.88 )
Ranked among companies with meaningful Price/Tangible Book only.
PBYI' s Price/Tangible Book Range Over the Past 10 Years
Min: 4.18  Med: 14.74 Max: 50.76
Current: 4.88
4.18
50.76
Earnings Yield (Greenblatt) (%) -23.83
PBYI's Earnings Yield (Greenblatt) (%) is ranked lower than
72% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. PBYI: -23.83 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PBYI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -23.83  Med: 0.00 Max: 0
Current: -23.83
-23.83
0

More Statistics

EPS $ -7.11
Beta0.49
Short Percentage of Float37.27%
52-Week Range $35.43 - 252.92
Shares Outstanding(Mil)32.44

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 277 1,165
EPS($) -7.32 -6.97 -1.95 11.84
EPS without NRI($) -7.32 -6.97 -1.95 11.84

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:0PB.Germany,
Puma Biotechnology Inc was incorporated in Delaware on April 27, 2007. The Company is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care It is engaged in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The Company currently licenses the rights to three drug candidates: PB272 (neratinib (oral)), which are being developed for the treatment of breast cancer patients, non-small cell lung cancer and patients with HER2 mutation-positive solid tumors; PB272 (neratinib (intravenous)), which are being developed for the treatment of cancer patients; and PB357, which it believes can serve as a backup compound to PB272, and which are being evaluated for further development. The Company focused on developing neratinib for the treatment of patients with human epidermal growth factor receptor type 2, or HER2-positive, breast cancer, HER2 mutated non-small cell lung cancer, HER2-negative breast cancer that has a HER2 mutation and other solid tumors that have an activating mutation in HER2. Therapeutic strategies, such as the use of Herceptin (trastuzumab), Perjeta (pertuzumab), and Kadcyla (T-DM1), produced by Genentech, and Tykerb (lapatinib), produced by GlaxoSmithKline, given either alone or in combination with chemotherapy, have been developed to improve the treatment of this cancer by binding to the HER2 protein. The Company licenses the exclusive rights to its current drug candidates from Pfizer Inc., or Pfizer, which had previously been responsible for the clinical trials regarding neratinib. The Company's competitors include Genentech, GlaxoSmithKline, Roche, Boehringer Ingelheim, Takeda, Array Biopharma and Ambit Biosciences.
» More Articles for PBYI

Headlines

Articles On GuruFocus.com
Hall of Fame/ Hall of Shame: The Best and Worst Recommendations of 2014 Jan 09 2015 

More From Other Websites
Puma Biotechnology to Participate in Fireside Chat at Leerink Partners Global Healthcare Conference Feb 03 2016
Coverage initiated on Puma Biotech. by Credit Suisse Jan 21 2016
What Factors Have These 4 Stocks in Dire Straits Today? Jan 11 2016
Puma Biotechnology Shareholders Overwhelmingly Reject Eshelman’s Consent Solicitation Jan 08 2016
Puma Biotechnology Shareholders Overwhelmingly Reject Eshelman’s Consent Solicitation Jan 08 2016
Puma Biotechnology to Present at J.P. Morgan Healthcare Conference Jan 04 2016
Puma Biotechnology to Present at J.P. Morgan Healthcare Conference Jan 04 2016
4 Top FDA Decisions Expected in Q1 Jan 02 2016
Second Leading Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders... Dec 30 2015
Third Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject... Dec 30 2015
Third Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject... Dec 30 2015
Second Leading Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders... Dec 29 2015
10 Biotechs Short Sellers Are Betting Against Dec 29 2015
PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 23 2015
ISS Says Puma Biotechnology Is In A 'Critical Stage' Of Turnaround Plan, Urges Investors To Vote... Dec 23 2015
ISS Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by... Dec 23 2015
ISS Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by... Dec 23 2015
PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events Dec 18 2015
Puma Biotechnology Expands Third Cohort in Phase II Trial of PB272 in HER2 Mutation Positive Cancer... Dec 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK